We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

1 hedge funds and large institutions have $3.16M invested in Hepion Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

709% more capital invested

Capital invested by funds: $390K → $3.16M (+$2.77M)

Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.03M

Top Sellers

Rank Fund Capital Flow
1
SIM
Spark Investment Management
New York
-$40K
2
TRCT
Tower Research Capital (TRC)
New York
-$3K
3
TDC
Thompson Davis & Co
Virginia
-$2K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$317
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.63M +$2.03M +1 New
Morgan Stanley
2
Morgan Stanley
New York
$708K – – –
BFA
3
BlackRock Fund Advisors
California
$315K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$131K – – –
EVC
5
Eidelman Virant Capital
Missouri
$76K – – –
PFS
6
Prospera Financial Services
Texas
$69K – – –
CS
7
Credit Suisse
Switzerland
$61K – – –
CC
8
Callan Capital
California
$52K – – –
Deutsche Bank
9
Deutsche Bank
Germany
$26K – – –
BA
10
BlackRock Advisors
Delaware
$19K – – –
BIT
11
BlackRock Institutional Trust
California
$19K – – –
BIM
12
BlackRock Investment Management
Delaware
$19K – – –
Wells Fargo
13
Wells Fargo
California
$18K – – –
VIA
14
Vantage Investment Advisors
Pennsylvania
$5K – – –
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$3K – – –
AIG
16
American International Group
New York
$1.44K – – –
Bank of America
17
Bank of America
North Carolina
$1K – – –
CAL
18
Capital Advisors Ltd
Ohio
$1K – – –
CA
19
CapWealth Advisors
Tennessee
$1K – – –
Manulife (Manufacturers Life Insurance)
20
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1 – – –
BNP Paribas Financial Markets
21
BNP Paribas Financial Markets
France
– -$317 – –
SIM
22
Spark Investment Management
New York
– -$40K – –
TDC
23
Thompson Davis & Co
Virginia
– -$2K – –
TRCT
24
Tower Research Capital (TRC)
New York
– -$3K – –

HEPA Hedge Fund Activity: Q2 2015 in Review

1 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2015, worth a combined $3.16M — up 709% from $390K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new HEPA positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $2.03M. The largest seller was Spark Investment Management, cutting an estimated $40K.

  • 1 institutional investor held Hepion Pharmaceuticals (HEPA) as of Q2 2015, up from 0 in Q1 2015.
  • Funds reported $3.16M of Hepion Pharmaceuticals stock for Q2 2015, up 709% quarter-over-quarter.
  • 1 fund opened new Hepion Pharmaceuticals positions in Q2 2015 and 0 closed out, a net change of +1 holder.
  • The largest Hepion Pharmaceuticals buyer in Q2 2015 was Vanguard Group, an estimated $2.03M added.
  • The largest Hepion Pharmaceuticals seller in Q2 2015 was Spark Investment Management, an estimated $40K sold.

Based on aggregated 13F filings for Q2 2015.